Tempus AI's growth and partnerships make it an attractive investment. See why TEM stock is a solid Buy due to its ...

Fintel reports that on November 11, 2024, Stifel downgraded their outlook for Tempus AI (NasdaqGS:TEM) from Buy to Hold. ...

周二，Piper Sandler调整了对Tempus AI Inc (NASDAQ:TEM)的展望，将该人工智能公司的股票目标价从此前的40美元上调至70美元。该公司维持对Tempus AI股票的中性评级。此次调整是在Tempus AI最近发布财报后做出的，财报是修订估值的一个因素。 Piper Sandler的分析师将财报作为上调目标价的主要原因。尽管做出了积极调整，但分析师指出，新的目标价并未 ...

Stifel Nicolaus analyst Daniel Arias downgraded the rating on Tempus AI, Inc. Class A (TEM – Research Report) to a Hold yesterday, ...

Stifel has downgraded Tempus AI (NASDAQ:TEM) to hold from buy, citing valuation and uncertainty about core growth in 2025.

周二，Piper Sandler调整了对Tempus AI Inc (NASDAQ:TEM)的展望，将目标价从此前的$40.00上调至$70.00。尽管做出了这一重大调整，但该公司仍维持对该股票的中性评级。 此次调整是在Tempus AI最近发布财报之后进行的，这份财报似乎提供了新的数据，促使分析师重新评估公司的股票价值。Piper Sandler的分析师注意到了公司的积极表现，但并未改变先前持有 ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.

As of November 08, 2024, Tempus AI, Inc had a $11.6 billion market capitalization, putting it in the 82nd percentile of companies in the Life Sciences Tools & Services industry. Tempus AI, Inc does ...

The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

Our Tempus AI Inc share price forecast data is based on consensus analyst prediction, covering public companies earnings per share and revenue. Assess the Tempus AI share price predictions. View ...